Canada to India Pharmaceutical Import

The pharmaceutical trade corridor between Canada and India has experienced significant growth over the past decade. In 2024, India imported pharmaceutical products valued at $37.54 million from Canada, marking a substantial increase from previous years. This upward trend reflects the strengthening of bilateral trade relations and India's growing demand for high-quality pharmaceutical formulations. The collaboration between Canadian suppliers and Indian buyers has been pivotal in this expansion, with 227 Canadian suppliers and 166 Indian buyers facilitating 3,250 shipments valued at an average of $16,000 each.

Canada's contribution to India's pharmaceutical imports is noteworthy, with a total import value of $51.1 million over the past five years. This positions Canada as a significant player in India's pharmaceutical supply chain. The top ten imported products from Canada include Simvastatin, Lactulose, Citalopram, Escitalopram, Fluticasone, Omeprazole, Tofacitinib, Atorvastatin, Paclitaxel, and Metformin, indicating a diverse range of therapeutic areas addressed by Canadian exports.

Between 2024 and 2026, several key developments have influenced the pharmaceutical trade between Canada and India. The Central Drugs Standard Control Organisation (CDSCO) has implemented policy changes to streamline the registration process for foreign pharmaceutical products, enhancing the ease of market entry for Canadian companies. Additionally, trade agreements and regulatory harmonization efforts have been initiated to bolster bilateral trade, focusing on mutual recognition of manufacturing standards and expedited customs procedures.

Canadian pharmaceutical companies seeking to import products into India must navigate the CDSCO registration process, which involves several critical steps. Initially, companies must register their manufacturing sites with CDSCO, a prerequisite for product registration. This process includes submitting an application with detailed information about the manufacturing facility, such as its address, contact details, and a copy of the manufacturing license. The registration is typically valid for five years, after which renewal is required. Once the manufacturing site is registered, companies can proceed to register individual products by submitting Form 40 or 41, depending on the product category. The registration process may be expedited if the product has been approved by recognized regulatory authorities, potentially waiving the need for local clinical trials. The overall timeline for product registration can vary, but it generally takes several months to complete.

India requires that foreign manufacturing sites adhere to Good Manufacturing Practices (GMP) standards as outlined by the World Health Organization (WHO). Manufacturers must provide evidence of compliance with these standards, which may include certificates from recognized authorities. CDSCO conducts inspections to verify adherence to GMP, ensuring that imported pharmaceutical products meet India's quality and safety requirements. Manufacturers are also encouraged to obtain WHO prequalification for their products, as this can facilitate smoother market entry and acceptance within India.

To import pharmaceutical products into India, Canadian companies must prepare and submit several key documents. These include an import license (Form 10), a registration certificate from CDSCO, a No Objection Certificate (NOC) from the manufacturer, a test license, and compliance with customs procedures. The import license is essential for the legal entry of pharmaceutical products into India, while the registration certificate confirms that the products have been approved by CDSCO. The NOC and test license are required to ensure that the products meet Indian standards and regulations. Adherence to customs procedures is crucial to facilitate the smooth clearance of goods through Indian ports.

India's pharmaceutical imports from Canada are predominantly in the form of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The top ten imported products encompass a range of therapeutic areas, with Simvastatin leading at $8.8 million, followed by Lactulose at $6.5 million, and Citalopram and Escitalopram each at $5.3 million. This diversity indicates that Canadian pharmaceutical exports to India address various medical needs, from cardiovascular to psychiatric conditions.

Canadian pharmaceutical companies export a variety of innovative and specialty products to India, including patented drugs, biologics, and novel formulations not manufactured domestically. These products often fill critical gaps in India's healthcare system, providing patients with access to advanced therapies. The importation of such products is facilitated by India's recognition of the quality and efficacy of Canadian pharmaceuticals, as well as the regulatory approvals granted by CDSCO.

India's demand for pharmaceutical imports from Canada is driven by several factors. The protection of intellectual property rights in Canada ensures that patented drugs are available for import, meeting the needs of patients requiring specific therapies. Additionally, Canada's advanced pharmaceutical manufacturing technologies and adherence to international quality standards address technology gaps in India. The high disease burden in India, coupled with the need for quality medications, further drives the importation of Canadian pharmaceutical products.

India's import tariff structure for pharmaceutical formulations includes a Most Favored Nation (MFN) tariff rate, basic customs duty, Integrated Goods and Services Tax (IGST), and health cess. The MFN tariff rate is applied to imports from countries with which India has trade agreements, while the basic customs duty is a standard tax imposed on imported goods. The IGST is applicable to all goods and services imported into India, and the health cess is a specific tax levied on certain goods, including pharmaceuticals, to fund health initiatives. These tariffs collectively impact the final cost of imported pharmaceutical products in India.

India and Canada have engaged in trade negotiations to enhance bilateral relations, focusing on mutual recognition of manufacturing standards and regulatory processes. While there is no comprehensive Free Trade Agreement (FTA) between the two countries, ongoing discussions aim to establish preferential duty rates and streamline customs procedures. These efforts are intended to facilitate smoother trade flows and encourage increased pharmaceutical imports from Canada to India.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, plays a significant role in the pharmaceutical import landscape. This section restricts the patenting of new forms of known substances unless they demonstrate enhanced efficacy. While this provision aims to prevent evergreening of patents, it can impact the availability of certain imported patented drugs. Additionally, the National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines, including imported drugs, to ensure affordability. This price control mechanism can influence the demand for imported pharmaceutical products from Canada.

Pharmaceutical shipments from Canada to India primarily utilize sea and air routes. Major sea routes involve transshipment through ports in Europe or the Middle East, with transit times ranging from 20 to 30 days, depending on the specific ports and shipping schedules. Air shipments are expedited, typically taking 5 to 7 days, and are often preferred for high-value or time-sensitive products. The reliability of these routes is generally high, with established shipping lines and air cargo services ensuring consistent delivery schedules.

In Canada, pharmaceutical exports are primarily handled through major ports such as the Port of Vancouver and the Port of Montreal, which are equipped with facilities to manage pharmaceutical shipments. In India, key import ports include the Jawaharlal Nehru Port in Mumbai and the Chennai Port, both of which have dedicated facilities for handling pharmaceutical products. These ports are equipped with the necessary infrastructure to ensure the safe and efficient handling of pharmaceutical imports.

Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance procedures, which include verification of import documentation, inspection of goods, and compliance with CDSCO regulations. CDSCO conducts testing to ensure that imported pharmaceutical products meet Indian quality standards. For temperature-sensitive products, maintaining the cold chain is critical. Indian customs authorities and logistics providers are equipped to handle cold chain requirements, ensuring that products are stored and transported at appropriate temperatures throughout the import process.

Despite being a major manufacturer of generic pharmaceuticals, India imports a significant portion of its pharmaceutical products, particularly patented drugs, biologics, and novel formulations not produced domestically. This dependency is driven by the need to access advanced therapies and address specific medical conditions that require specialized treatments. Canada's pharmaceutical exports play a crucial role in meeting these needs, providing high-quality products that complement India's domestic manufacturing capabilities.

Major Canadian pharmaceutical companies, such as Apotex, have established a presence in India through direct exports and partnerships with local firms. These companies employ strategies like contract manufacturing and joint ventures to navigate the Indian market effectively. By collaborating with Indian partners, Canadian firms can leverage local market knowledge and distribution networks, enhancing their reach and competitiveness in the Indian pharmaceutical sector.